UK researchers develop medical patch to treat mucosal conditions

26 June 2018 (Last Updated June 26th, 2018 11:55)

Researchers at the University of Sheffield in the UK have partnered with Denmark-based firm Dermtreat to develop a new biodegradable plaster called Rivelin for the treatment of oral conditions.

UK researchers develop medical patch to treat mucosal conditions
The biodegradable patch has a long adhesion time and high flexibility which conforms to the surface inside the mouth. Credit: The University of Sheffield.

Researchers at the University of Sheffield in the UK have partnered with Denmark-based firm Dermtreat to develop a new biodegradable plaster called Rivelin for the treatment of oral conditions.

The patch is made of special polymers that can stick to moist surfaces. It directly administers steroids to oral ulcers or lesions and forms a protective barrier around the affected area to speed-up its healing process.

“The plaster can be used to treat various mucosal conditions, including oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS), which lead to erosive and painful lesions in 1% to 2% of the population.”

Existing treatments for oral conditions comprise mouthwashes, creams and ointments that need to be used in the whole mouth, and are usually ineffective because of inadequate drug contact time with the lesion.

On the contrary, the new Rivelin patch is said to possess long adhesion time and high flexibility.

University of Sheffield School of Clinical Dentistry Oral Bioscience reader Craig Murdoch said: “The patch acts like a plaster inside your mouth, which means it is very effective at directly targeting the specific area as well as forming a protective barrier.

“Patients who have trialled the patch found it to be very comfortable to wear and they were really pleased with the length of adhesion which makes it particularly effective and efficient.”

The plaster can be used to treat various mucosal conditions, including oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS), which lead to erosive and painful lesions in 1% to 2% of the population.

Dermtreat plans to use its recent $17.7m funding to evaluate the Rivelin patch in Phase II clinical trials at multiple UK and US clinical sites.

The company is additionally sponsoring further studies to create the next generation of patches that will carry other useful drugs.